Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ163MR)

This product GTTS-WQ163MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ163MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14477MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ6698MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ7225MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ6659MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ15812MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ3886MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ6188MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ10534MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3015014
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW